James B. Francis, CFA
Chief Research Officer, CRB Monitor
In episode three of Cannabis Q&A, James Francis is joined by Oren Shuster, CEO and Board member of IM Cannabis Corp., a multinational medical cannabis company that is focused on offering a full spectrum of government-licensed cannabis products, for both wholesale and retail clients. The IM Cannabis ecosystem operates in Israel through its commercial relationship with Focus Medical Herbs Ltd. where it cultivates, imports, and distributes cannabis to medical patients, leveraging years of proprietary data and patient insights. In Germany, IM Cannabis operates through Adjupharm GmbH, where it also distributes cannabis to medical patients.
IM Cannabis, a Tier 1B cannabis related business (CRB), is not only covered by the CRB Monitor research team but is also a constituent of the Nasdaq CRB Monitor Index Universe of CRBs.
Mr. Shuster shared his insights into several topics related to the cannabis industry and his company, discussing the near term and in going forward:
- How Oren's extensive background in technology has been an advantage in launching a cannabis company
- His outlook for the global macroeconomy and its implications for the cannabis industry
- The global regulatory environment for cannabis legalization, particularly Israel and Europe
- Mr. Shuster's plan for growth as he leads IM Cannabis in this challenging environment
Wondering what a Tier 1, Tier 2 or Tier 3 CRB is?
See our seminal ACAMS Today white paper Defining "Marijuana-Related Business" and its update Defining "Cannabis-Related Business"